Health Care & Life Sciences » Biotechnology | Northwest Biotherapeutics Inc.

Northwest Biotherapeutics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
65,789.00
135,634.00
114,741.00
80,214.00
73,143.00
35,794
Depreciation, Depletion & Amortization
11.00
11.00
56.00
189.00
439.00
1,291
Other Funds
-
1,902.00
287.00
-
-
1,027
Funds from Operations
52,285.00
78,668.00
84,955.00
74,996.00
44,550.00
35,530
Changes in Working Capital
14,485.00
24,092.00
6,347.00
19,344.00
8,055.00
944
Net Operating Cash Flow
37,800.00
54,576.00
78,608.00
55,652.00
36,495.00
34,586
Capital Expenditures
-
33,727.00
6,751.00
4,939.00
8.00
Sale of Fixed Assets & Businesses
1.00
-
-
-
-
Net Investing Cash Flow
1.00
36,352.00
6,751.00
4,939.00
212.00
Issuance/Reduction of Debt, Net
4,669.00
24,465.00
4,859.00
5,710.00
8,721.00
Net Financing Cash Flow
48,952.00
85,819.00
94,238.00
38,308.00
34,290.00
Net Change in Cash
11,153.00
5,109.00
8,423.00
16,177.00
6,754.00
Free Cash Flow
-
88,303.00
85,359.00
60,591.00
36,503.00
Other Sources
-
-
-
-
220.00
Change in Capital Stock
53,621.00
63,256.00
89,092.00
32,598.00
25,569.00
Exchange Rate Effect
-
-
456.00
6,106.00
4,761.00
Other Uses
-
2,625.00
-
-
-

About Northwest Biotherapeutics

View Profile
Address
4800 Montgomery Lane
Bethesda Maryland 20814
United States
Employees -
Website http://www.nwbio.com
Updated 07/08/2019
Northwest Biotherapeutics, Inc. is a clinical stage biotechnology company. The firm engages in the development of cancer vaccines designed to treat solid tumor cancers. It also offers a platform technology for DCVax dendritic cell-based vaccines.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.